INCY Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Suppor
INCY Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers Rapid oral presentations will highlight new Phase 1 data across Incyte's solid tumor portfolio Both INCB161734, an investigational, potent, Selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFßR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively
INCY Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers Rapid oral presentations will highlight new Phase 1 data across Incyte's solid tumor portfolio Both INCB161734, an investigational, potent, Selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFßR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively